Bruce C. Conway
Director/Board Member chez Trigemina, Inc.
Profil
Bruce C.
Conway is currently a Director at Trigemina, Inc. He was previously a Director at Whitehall Corp.
and an Independent Director at Clearpoint Neuro, Inc. from 2011 to 2013.
Postes actifs de Bruce C. Conway
| Sociétés | Poste | Début |
|---|---|---|
Trigemina, Inc.
 Trigemina, Inc. Pharmaceuticals: MajorHealth Technology Trigemina, Inc. develops drugs to control pain and migraine headache. Its platform is based on proprietary formulations of oxytocin, a naturally-occurring hormone, delivered through nasal-cerebral pathways for the treatment of a large spectrum of chronic and acute neurological disorders. The company was founded by David C. Yeomans in 2006 and is headquartered in Moraga, CA. | Director/Board Member | - |
Anciens postes connus de Bruce C. Conway
| Sociétés | Poste | Fin |
|---|---|---|
| CLEARPOINT NEURO, INC. | Director/Board Member | 12/04/2013 |
Whitehall Corp.
 Whitehall Corp. Aerospace & DefenseElectronic Technology Part of Waste Connections, Inc., Whitehall Corp. is a private company that makes and sells marine sensing systems. The company is based in Dallas, TX. Whitehall was acquired by Aviation Sales Co. on July 31, 1998 for $103.27 million. | Director/Board Member | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CLEARPOINT NEURO, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Whitehall Corp.
Whitehall Corp. Aerospace & DefenseElectronic Technology Part of Waste Connections, Inc., Whitehall Corp. is a private company that makes and sells marine sensing systems. The company is based in Dallas, TX. Whitehall was acquired by Aviation Sales Co. on July 31, 1998 for $103.27 million. | Electronic Technology |
Trigemina, Inc.
Trigemina, Inc. Pharmaceuticals: MajorHealth Technology Trigemina, Inc. develops drugs to control pain and migraine headache. Its platform is based on proprietary formulations of oxytocin, a naturally-occurring hormone, delivered through nasal-cerebral pathways for the treatment of a large spectrum of chronic and acute neurological disorders. The company was founded by David C. Yeomans in 2006 and is headquartered in Moraga, CA. | Health Technology |
